Track DNTH and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Dianthus Therapeutics Inc.
7 Times Square, New York, NY, United States, 10036
IPO
2023
Employees
92
Industry
Biotechnology
Sector
Healthcare
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20261-1
0
Q1 20264-4
0
Q4 20253-3
0
Q3 20251-1
0
4-quarter cumulative
9 sells0 buys
Analyst Ratings
2 analysts covering
Buy100%recommend buy
Buy
2
Hold
0
Sell
0